| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440409 | European Journal of Cancer | 2018 | 6 Pages |
Abstract
Nab-paclitaxel plus ramucirumab combination therapy shows promising activity and manageable toxicities and could be a useful second-line treatment option for patients with previously treated advanced gastric cancer.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, Atsuo Takashima, Kensei Yamaguchi, Norisuke Nakayama, Takehiro Takahashi, Eiji Oki, Mizutomo Azuma, Tomohiro Nishina, Shuichi Hironaka, Yoshito Komatsu, Kohei Shitara,